BNP Paribas Financial Markets’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-252
| Closed | -$69 | – | 4973 |
|
|
2022
Q3 | $69 | Hold |
252
| – | – | ﹤0.01% | 4662 |
|
|
2022
Q2 | $88 | Hold |
252
| – | – | ﹤0.01% | 4023 |
|
|
2022
Q1 | $171 | Sell |
252
-185
| -42% | -$203 | ﹤0.01% | 4082 |
|
|
2021
Q4 | $1.01K | Sell |
437
-50
| -10% | -$169 | ﹤0.01% | 4054 |
|
|
2021
Q3 | $2.23K | Hold |
487
| – | – | ﹤0.01% | 3786 |
|
|
2021
Q2 | $2.16K | Sell |
487
-1,616
| -77% | -$8.22K | ﹤0.01% | 3874 |
|
|
2021
Q1 | $15.3K | Sell |
2,103
-979
| -32% | -$8.05K | ﹤0.01% | 3795 |
|
|
2020
Q4 | $23.5K | Sell |
3,082
-157
| -5% | -$1.05K | ﹤0.01% | 3813 |
|
|
2020
Q3 | $29.4K | Buy |
3,239
+1,911
| +144% | +$14.5K | ﹤0.01% | 3692 |
|
|
2020
Q2 | $11.2K | Sell |
1,328
-1,469
| -53% | -$9.67K | ﹤0.01% | 3655 |
|
|
2020
Q1 | $13.8K | Buy |
2,797
+1,614
| +136% | +$12.6K | ﹤0.01% | 3983 |
|
|
2019
Q4 | $8.52K | Sell |
1,183
-151
| -11% | -$1.36K | ﹤0.01% | 4146 |
|
|
2019
Q3 | $14.4K | Buy |
1,334
+371
| +39% | +$3.97K | ﹤0.01% | 4076 |
|
|
2019
Q2 | $12.5K | Buy |
+963
| New | +$12.8K | ﹤0.01% | 4054 |
|
BNP Paribas Financial Markets's LOGC Position: Q4 2022 in Review
BNP Paribas Financial Markets sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 252 shares — an estimated $69 sold.
BNP Paribas Financial Markets first reported a position in LOGC in Q2 2019 and held it in 14 quarters. The position peaked at $29.4K in Q3 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- BNP Paribas Financial Markets reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- BNP Paribas Financial Markets sold 252 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $69.
- BNP Paribas Financial Markets first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
- BNP Paribas Financial Markets's LogicBio Therapeutics, Inc. Common Stock position peaked at $29.4K in Q3 2020.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.